Prescient Therapeutics signs deal with Q-Gen to enable OmniCAR clinical trials
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has entered a services agreement with specialist cell therapy manufacturer...
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has entered a services agreement with specialist cell therapy manufacturer...
Precedence Research suggests the global cancer therapeutics market size is predicted to surpass US$365.99 billion...
“The fact of the matter is there are people walking around now who shouldn’t be...
Clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX) has provided an upbeat update for the June 2022...
It’s quarterlies season as the ASX market announcements page becomes increasingly flooded with lodgements. The...
Prescient Therapeutics (PTX) advanced multiple clinical programs for its targeted and cell therapy drugs over...
Prescient Therapeutics Ltd (ASX:PTX)’s PTX-100 for the treatment of peripheral T-cell lymphomas (PTCL) has been...
The granting of an Orphan Drug Designation by the US FDA will grant PTX-100 market...
Prescient Therapeutics (ASX: PTX) Managing Director and CEO Steven Yatomi-Clarke presents at the Switzer Small...
Prescient Therapeutics Ltd (ASX:PTX) has been granted a US patent for its flagship OmniCAR portfolio entitled...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.